What are China’s ethical review requirements for foreign clinical trials?

What Are China’s Ethical Review Requirements for Foreign Clinical Trials?

Ethical review is a foundational requirement for conducting clinical trials in China — and the volume of trials involving foreign sponsors has grown dramatically, from approximately 500 annually in 2015 to over 2,000 in 2024, making China the second-largest clinical trial market globally after the United States. Since the 2017 ICH membership and the subsequent adoption of ICH GCP E6(R2) guidelines, China’s ethical review framework has progressively aligned with international standards. However, significant China-specific requirements remain — including mandatory ethics committee registration with the NMPA, distinct informed consent documentation standards, and a unique multi-tiered review system for foreign-sponsored trials involving biological samples, genetic data, and special populations. Foreign sponsors should budget 3-6 months for the complete ethical review and regulatory approval process in China, with total ethics committee costs ranging from ¥30,000 to ¥100,000 ($4,200 to $14,000) per trial site.

Short answer: Foreign companies conducting clinical trials in China must obtain ethical review from an NMPA-registered ethics committee (EC/IRB) at each trial site, following the requirements of the Good Clinical Practice (GCP) guidelines (NMPA Order No. 57, 2020), the Ethical Review of Biomedical Research Involving Human Subjects (NHFPC Decree No. 11, 2016), and China’s Human Genetic Resource Management Regulations (State Council Decree, effective 2023). The process involves initial review (60-90 days), ongoing review (annual or more frequent), and specific requirements for vulnerable populations, genetic data, and biospecimen export. Foreign trial sponsors should engage a Chinese contract research organization (CRO) to navigate the dual regulatory pathway of NMPA clinical trial approval and ethics committee review, which run concurrently rather than sequentially.

Regulatory Framework

China’s ethical review framework for clinical trials is built on four key regulatory pillars:

Ethics Committee Structure and Registration

Short answer: Ethics committees (ECs) in China must be registered with the NMPA’s Drug Clinical Trial Registration and Information Platform (药物临床试验登记与信息公示平台). Each clinical trial site must have its own EC review — a single, centralized IRB review does not substitute for site-level review in China, unlike in the United States.

What to know: Per China’s GCP (2020), an ethics committee must have at least 11 members with diverse backgrounds in medicine, pharmacy, nursing, law, and ethics. At least one member must be an independent community representative. The committee must include both men and women, and members cannot participate in reviews of trials in which they have a financial or professional conflict of interest. As of 2025, approximately 1,200 ethics committees are registered with the NMPA’s platform — but only about 700 are classified as “Tier 3” (三级甲等 hospital-affiliated) committees qualified to review foreign-sponsored drug and device clinical trials. Foreign sponsors should verify the registration status and review capabilities of each potential trial site’s EC before submitting applications.

Ethical Review Process

Initial Review

Short answer: The initial ethical review process for a foreign-sponsored clinical trial takes 60-90 days from submission to final decision. The review covers the trial protocol, investigator qualifications, informed consent form, subject recruitment materials, and the investigator’s brochure.

What to know: The initial review process follows a defined sequence:

1. Submission (Week 1): Foreign sponsors submit the complete ethics dossier through the site’s EC — typically via both physical paper (still required by most Chinese hospitals) and electronic platform. The dossier must include Chinese-language versions of all documents.
2. Administrative review (Week 2-3): The EC secretariat checks the dossier for completeness and forwards it to designated primary and secondary reviewers.
3. Full board review (Week 4-8): The full EC convenes to discuss the trial. In China, EC meetings are typically held monthly or bi-monthly (unlike weekly reviews common in the US and EU). Foreign sponsors should align their submission timeline with the EC’s meeting schedule to avoid 4-8 week delays.
4. Decision and follow-up (Week 9-12): The EC issues a formal written decision: approval, conditional approval (with modifications), or rejection. Conditional approval — the most common outcome for foreign-sponsored trials — requires the sponsor to submit revised documents addressing EC concerns, which are reviewed by the designated reviewers (not the full board) in a follow-up review cycle taking 2-4 weeks.

Continuous and Ongoing Review

Short answer: After initial approval, ethics committees require annual review (年度跟踪审查) and may require more frequent progress reports for higher-risk trials. Any protocol amendments, serious adverse events (SAEs), or new safety information must be submitted for EC review within specified timelines.

What to know: Key ongoing review requirements include:

• Annual report: Must be submitted within 30 days of the anniversary of the initial approval date. The EC has 15 working days to review and respond.
• SAE reporting: Fatal or life-threatening SAEs must be reported to the EC within 7 days (calendar) of the investigator becoming aware; other SAEs within 15 days. However, the requirement differs from US/UK practice: in China, SAEs are reported to the EC, the NMPA, and the National Health Commission simultaneously, and the sponsor must provide a Chinese-language summary report.
• Protocol amendments: Substantial amendments require full board review before implementation. Minor administrative amendments (personnel changes, minor editorial corrections) can be reviewed through expedited review by the EC chair or designated reviewers.
• Trial suspension/termination: If the sponsor or investigator suspends or terminates a trial, the EC must be notified within 24 hours with a detailed explanation.

Informed Consent Requirements

Short answer: China’s informed consent requirements are broadly aligned with ICH GCP E6(R2) but include several China-specific elements: mandatory inclusion of genetic data consent language, a unique “compensation and insurance” section, and a requirement that the consent form be signed by both the subject and the investigator (not just the subject).

What to know: The informed consent form (ICF) for clinical trials in China must include the following elements per NMPA Order No. 57:

Human Genetic Resource (HGR) Management

Short answer: Since the 2023 revision of the Human Genetic Resource Management Regulations, any clinical trial involving the collection, storage, or export of Chinese human genetic resources (blood, tissue, DNA, RNA, cells) requires separate ethical review and regulatory approval from the Ministry of Science and Technology (MOST). This applies to virtually all clinical trials where biological samples are collected and analyzed.

What to know: The HGR approval process runs parallel to but independently from the NMPA clinical trial approval and EC ethical review. Key requirements for foreign sponsors include:

1. Dual ethical review: The research must first receive EC approval, after which the HGR application is submitted to MOST. The EC approval must explicitly address HGR-related ethical considerations (sample collection volume, storage duration, data confidentiality, and export necessity).
2. Prior informed consent for HGR use: The ICF must include a separate, clear explanation of how human genetic resources will be handled. This consent cannot be bundled with general clinical trial consent — it must be a distinct checkbox or signature block.
3. China-based collaborator requirement: Foreign sponsors must partner with a Chinese institution (hospital or university) as the HGR project leader. The Chinese partner submits the HGR application and assumes primary responsibility for compliance. This typically requires a data-sharing agreement between the foreign sponsor and the Chinese institution.
4. Prohibition on full-sample export: The 2023 regulations generally prohibit exporting whole blood, tissue, or cell samples outside China. Only extracted data (genomic sequencing results, proteomic data, metabolomic profiles) may be transferred abroad — and only after MOST approval. This has significant implications for foreign sponsors’ central laboratory strategies: biomarker analysis must typically be conducted at Chinese-certified laboratories.
5. Approval timeline: HGR approval typically takes 60-90 days from submission. Foreign sponsors should factor this timeline into their overall clinical trial planning, as the trial cannot commence until both NMPA approval and HGR approval are obtained.

Special Populations and Vulnerable Subjects

Short answer: Clinical trials involving special populations — minors, pregnant women, prisoners, mentally incapacitated adults, geriatric patients — require additional ethical safeguards in China, including enhanced informed consent procedures, independent monitoring, and in some cases, approval from a centralized NHC ethics committee rather than a local hospital EC.

What to know: China has specific ethical review requirements for several categories of vulnerable subjects:

• Minors (儿科试验): Pediatric clinical trials require the subject’s assent (if aged 8-17) plus parental/guardian consent. The EC must include a pediatric specialist or independent pediatric advocate. A parent or guardian must be present during trial procedures.
• Cognitive impairment: For subjects with dementia, intellectual disability, or mental illness, consent must be obtained from a legal guardian. If no legal guardian has been appointed (common in China), the EC may require appointment of a temporary guardian through civil procedures.
• Emergency research: Emergency research (e.g., trauma, stroke, cardiac arrest) follows deferred consent procedures similar to the US FDA Exception from Informed Consent (EFIC). However, China requires that the EC specifically approve the emergency research protocol in advance, and that the subject (or family member) is informed as soon as practical.
• Healthy volunteers: Phase I trials involving healthy Chinese volunteers raise specific ethical concerns about “therapeutic misconception” and payment inducement. The EC must review subject compensation amounts to ensure they are not coercive. The standard compensation range for healthy volunteer Phase I studies in China is ¥300-800 ($42-112) per visit.

Data Privacy and PIPL Compliance

Short answer: Since China’s Personal Information Protection Law (PIPL) took effect in November 2021, clinical trial sponsors — including foreign companies — must comply with comprehensive data privacy requirements that affect subject data collection, storage, transfer, and deletion. Health data is classified as “sensitive personal information” under PIPL and requires enhanced protection.

What to know: PIPL implications for foreign-sponsored clinical trials include:

1. Separate consent for health data processing: Subject consent for health data processing must be separate from general clinical trial consent. The ICF should include a distinct section explaining what health data will be collected, why, for how long it will be stored, and with whom it will be shared.
2. Data localization requirement: Health data collected from clinical trial subjects in China must be stored in China. Foreign sponsors must establish data storage infrastructure in China — typically through a cloud service provider (Alibaba Cloud, Tencent Cloud, AWS China) or a local data center.
3. Cross-border data transfer: Transferring clinical trial data (de-identified or not) outside China requires either (a) passing a government-administered security assessment (for data deemed “important” by regulators), (b) participating in a standard contractual clause mechanism, or (c) obtaining PIPL certification. Most foreign sponsors handling clinical trial data use the standard contractual clause route, which requires disclosure to subjects of the data recipient, purpose, and duration.
4. Data retention and deletion: PIPL requires data deletion upon the fulfillment of the original processing purpose. For clinical trial data, this means determining a retention period that satisfies both GCP requirements (typically 15 years per NMPA GCP) and PIPL deletion obligations — a tension that is not yet fully resolved in regulatory guidance.

Recent Policy Changes and Trends

Short answer: Several regulatory developments since 2023 have streamlined ethical review for foreign-sponsored clinical trials while simultaneously strengthening oversight of genetic data, data privacy, and vulnerable population protections.

What to know: Three key trends are shaping the ethical review landscape:

1. Centralized ethical review for multi-center trials: The 2023 Ethical Review Measures established a “lead EC” model for multi-center trials — the lead site’s EC (typically at a top-tier hospital) conducts the primary review, and other sites’ ECs accept the lead EC’s decision with site-specific modifications. This reduces the review burden from 10+ separate EC reviews to 1 primary + 9 focused site-level reviews, cutting the total review timeline from 4-6 months to 2-3 months for multi-center trials.
2. Streamlined HGR approval: In 2024, MOST introduced a “fast-track” HGR approval process for low-risk, non-controversial genetic research (e.g., routine biomarker analysis in late-stage clinical trials). Approval timelines were reduced from 60-90 days to 30-45 days for qualifying studies.
3. Electronic informed consent (eConsent): The 2023 Ethical Review Measures formally recognized electronic informed consent as legally equivalent to paper consent, enabling remote consent processes for decentralized clinical trials. This has been particularly beneficial for post-market studies and real-world evidence collection.

Where to Go From Here

Based on what you just read:

• Ready to act? Read [guide: SLUG-TO-BE-FILLED]
• Still comparing? See [comparison: SLUG-TO-BE-FILLED]
• Need numbers? Try [tool: SLUG-TO-BE-FILLED]

— China Gateway 360 —
Remote China market entry support, built around execution.